Quick Answer
Cytosorbents Corp reported Cash and Equivalents of $6.25 million for fiscal year 2025.
Cytosorbents Corp Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $6.25M | +90.5% |
| 2024 | $3.28M | -76.8% |
| 2023 | $14.13M | -36.2% |
| 2022 | $22.14M | -57.5% |
| 2021 | $52.14M | -27.0% |
| 2020 | $71.42M | +483.9% |
| 2019 | $12.23M | -45.3% |
| 2018 | $22.37M | +29.1% |
| 2017 | $17.32M | +230.2% |
| 2016 | $5.25M | -1.3% |
| 2015 | $5.32M | +47.5% |
| 2014 | $3.61M | +65.2% |
| 2013 | $2.18M | +26.2% |
| 2012 | $1.73M | +45.7% |
| 2011 | $1.19M | +12.4% |
| 2010 | $1.06M | -33.8% |
| 2009 | $1.60M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $7.54M | +32.6% | -26.1% |
| June 30, 2025 | $10.20M | +20.6% | -11.9% |
| March 31, 2025 | $11.59M | +34.6% | +253.3% |
| December 31, 2024 | $3.28M | -76.8% | -42.3% |
| September 30, 2024 | $5.69M | -32.0% | -32.8% |
| June 30, 2024 | $8.46M | -35.7% | -1.7% |
| March 31, 2024 | $8.61M | -54.8% | -39.1% |
| December 31, 2023 | $14.13M | -36.2% | +69.1% |
- Cytosorbents Corp showed an increase of +90.5% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2009–2025 period, Cytosorbents Corp’s cash and equivalents has grown by 291.6% (from $1.60 million to $6.25 million).
- The most recent figure is from Cytosorbents Corp’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 30, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: